What Is Alzheimer's Disease?
The 20-Year Head Start Nobody Talks About
In 2010, a team of researchers at Washington University in St. Louis did something remarkable. They took a group of cognitively normal adults, people who scored perfectly on every memory and reasoning test, and scanned their brains with PET imaging to measure amyloid-beta deposits.
About a third of these "perfectly healthy" participants had significant amyloid buildup. Their brains were already under assault. And they had no idea.
The researchers followed these people over the next decade. By 2020, the participants with high amyloid burden were three to five times more likely to have developed cognitive impairment than those with clean scans. The protein had been there all along, silently dismantling their neural architecture while they aced their cognitive tests and lived their normal lives.
This is the central, disturbing truth about Alzheimer's disease: it's a 20-year process, and the part we notice, the forgetting, the confusion, the gradual loss of self, is only the final act. By the time someone walks into a neurologist's office and says "I keep forgetting things," the war is already lost in major parts of the brain.
Which raises the obvious question. If the disease is building for two decades in silence, is there any way to hear it coming?
The Two Villains: A Protein Crime Story
Alzheimer's disease is fundamentally a story about two proteins gone wrong. Understanding those proteins, really understanding them, is the key to understanding everything else about the disease.
Villain #1: Amyloid-Beta
Every neuron in your brain produces a protein called amyloid precursor protein, or APP. It's a large protein that sits in the cell membrane, poking through from the inside to the outside. Scientists still aren't entirely sure what APP does in its normal state. It seems to play roles in cell signaling, synaptic function, and neural development. But the important thing is what happens when the cell is done with it.
When a neuron recycles APP, it uses enzymes called secretases to cut the protein into smaller fragments. There are two pathways. In the normal pathway, an enzyme called alpha-secretase makes the first cut, producing harmless fragments that dissolve and get cleared away. No problem.
But there's an alternative pathway. If beta-secretase makes the first cut instead of alpha-secretase, and then gamma-secretase makes a second cut, the result is a small, 42-amino-acid fragment called amyloid-beta 42 (A-beta 42). This fragment is sticky. Really sticky. It folds in on itself in a way that exposes hydrophobic regions, causing individual A-beta 42 molecules to clump together.
First they form small clumps called oligomers. Then longer chains called protofibrils. Then dense, insoluble deposits called amyloid plaques.
And here's where the "I had no idea" moment comes in. For decades, researchers assumed the plaques were the main problem. The "amyloid cascade hypothesis" proposed that plaques crush and kill nearby neurons. But more recent research has flipped this understanding on its head. It's not the plaques that are most toxic. It's the smaller oligomers, the precursors to plaques.
Amyloid-beta oligomers are small enough to float freely through the brain's interstitial fluid. They bind to synapses and disrupt neurotransmission. They trigger inflammatory responses. They damage the mitochondria that power neurons. And they interfere with the brain's waste-clearance system, creating a vicious cycle where the brain produces toxic amyloid fragments faster than it can remove them.
The plaques, paradoxically, may actually be a defense mechanism. By sequestering loose A-beta 42 into dense, immobile deposits, the brain may be trying to get the toxic oligomers out of circulation. It doesn't work well enough, but it means the plaques themselves are more like a crime scene marker than the weapon.
Villain #2: Tau
If amyloid is the instigator, tau is the executioner.
Tau is a structural protein. In a healthy neuron, tau proteins stabilize microtubules, the long cylindrical structures that serve as the cell's internal highway system. Microtubules transport everything: neurotransmitter vesicles heading to the synapse, mitochondria being shuttled to wherever energy is needed, waste products heading for disposal. Without functional microtubules, a neuron is like a city where every road has been destroyed.
In Alzheimer's, tau becomes hyperphosphorylated. Extra phosphate groups get attached to the protein, causing it to change shape. The misshapen tau can no longer grip the microtubules. It detaches, and the unsupported microtubules collapse.
But the freed tau doesn't just float harmlessly in the cell. It sticks to other tau proteins, forming paired helical filaments that twist together into neurofibrillary tangles. These tangles are dense, insoluble, and essentially permanent. Once a neuron develops tangles, it's doomed.
One of the most alarming discoveries in Alzheimer's research is that pathological tau spreads from neuron to neuron, almost like an infection. When a damaged neuron releases misfolded tau proteins into the extracellular space, neighboring neurons take them up. Inside the new host cell, the misfolded tau acts as a template, causing normal tau proteins to misfold in the same way. This "prion-like" spreading mechanism explains why tau pathology progresses through the brain in a predictable, sequential pattern, following the neural circuits that connect affected regions.
Here's the critical relationship between the two villains. Amyloid pathology typically appears first, sometimes decades before tau pathology. But tau tangles correlate much more closely with cognitive decline. You can have massive amyloid deposits and relatively preserved cognition. But once tau tangles appear in the hippocampus, memory loss follows.
The current understanding is that amyloid sets the stage by creating a toxic environment, and tau delivers the killing blow.
The Map of Destruction: How Alzheimer's Moves Through the Brain
One of the most remarkable things about Alzheimer's is how predictable its path is. In the 1990s, the German neuropathologists Heiko and Eva Braak meticulously mapped the progression of tau pathology through the brain, creating what's now known as the Braak staging system. Their work revealed that Alzheimer's follows the same route through the brain in virtually every patient.
Stage I-II: The Transentorhinal Region. Tau tangles first appear in the transentorhinal cortex, a narrow strip of tissue that serves as the gateway between the hippocampus and the rest of the cortex. At this stage, there are no clinical symptoms. Cognitive tests are normal. The brain is compensating.
Stage III-IV: The Limbic System. Tangles spread into the hippocampus and the surrounding limbic structures. This is where memory encoding happens. At this stage, subtle memory problems begin to emerge. A person might struggle to remember recent conversations, get confused about dates, or lose track of what they were doing. Clinical tests may show mild cognitive impairment.
Stage V-VI: The Neocortex. Tangles spread into the association cortices, the vast regions of the cerebral cortex responsible for language, spatial reasoning, executive function, and social cognition. This is when Alzheimer's becomes unmistakable. Language breaks down. The ability to dress, cook, and manage daily activities deteriorates. Eventually, even basic functions like swallowing and walking are affected.
The entire journey from Stage I to Stage VI typically takes 15 to 25 years. Most of that time is spent in the earliest stages, with the brain compensating and the person unaware.
Your Brain Is Screaming. Here's What EEG Hears.
Here's the thing about Alzheimer's that makes EEG so relevant: the disease doesn't just kill neurons. It disrupts the communication patterns between them long before they die. And those communication patterns are exactly what EEG measures.
A healthy brain produces a rich symphony of electrical oscillations. alpha brainwaves (8-13 Hz) ripple across the posterior cortex when you're relaxed and awake. beta brainwaves (13-30 Hz) dominate when you're actively thinking. Gamma waves (30-100 Hz) flash when you're binding information together, integrating a face with a name with a memory. theta brainwaves (4-8 Hz) pulse in the hippocampus during memory formation.
Alzheimer's disrupts this symphony in predictable ways.
The alpha rhythm slows and weakens. In healthy adults, the peak alpha frequency is typically around 10 Hz. In Alzheimer's patients, this peak shifts downward to 8 Hz or lower. Eventually the alpha rhythm may disappear entirely, replaced by diffuse theta activity. This slowing reflects the degeneration of thalamocortical circuits, the loops between the thalamus and cortex that generate and maintain the alpha rhythm.
Theta and delta power increase. As more neurons die and more connections degrade, the brain produces increasingly slow oscillations. High theta and delta activity during waking states is a hallmark of moderate to severe Alzheimer's, and represents the brain's failure to maintain the fast, coordinated activity required for normal cognition.
Coherence collapses. Coherence, the synchronization of electrical activity between different brain regions, is a measure of functional connectivity. In Alzheimer's, coherence drops progressively, first between frontal and posterior regions, then between the two hemispheres. This mirrors the physical disconnection caused by white matter degeneration and synaptic loss.
Gamma oscillations are impaired. Gamma waves, the fastest brain oscillations, are essential for memory encoding and cognitive binding. Alzheimer's significantly reduces gamma power and gamma-theta coupling (the locking of gamma bursts to specific phases of the theta cycle). This disruption of gamma activity is one reason why memory formation fails so catastrophically in the disease.
| EEG Feature | Healthy Brain | Alzheimer's Brain | What It Reflects |
|---|---|---|---|
| Alpha peak frequency | ~10 Hz | Below 8 Hz, eventually absent | Thalamocortical circuit degeneration |
| Theta power | Low during waking tasks | Elevated, especially frontally | Neural slowing, metabolic decline |
| Delta power | Minimal during waking | Increased in moderate-severe stages | Widespread neuronal dysfunction |
| Frontal-posterior coherence | High during cognitive tasks | Progressively reduced | Disconnection of brain networks |
| Gamma power | Strong during memory tasks | Significantly reduced | Failure of cognitive binding |
| P300 latency | ~300 ms | Delayed, often 400+ ms | Slowed cognitive processing |
Catching the Whisper Before the Scream
The most exciting development in Alzheimer's EEG research isn't about diagnosing people who already have symptoms. It's about catching the disease during that long, silent preclinical phase.
Multiple longitudinal studies have now demonstrated that EEG abnormalities precede clinical symptoms by years. A landmark 2023 study in Brain followed 800 participants over 12 years, collecting EEG data every 18 months. The researchers identified a set of EEG features, including reduced alpha peak frequency, increased frontal theta power, and decreased alpha-theta ratio, that predicted conversion from normal cognition to mild cognitive impairment with 74% accuracy, on average 5.5 years before diagnosis.
Another study, published in Neurobiology of Aging, focused specifically on participants carrying the APOE e4 gene variant, the strongest genetic risk factor for late-onset Alzheimer's. They found that e4 carriers showed altered EEG connectivity patterns as early as age 50, decades before the typical age of Alzheimer's onset. These patterns were not detectable by cognitive testing.
The key insight from this research is that the brain's electrical network degrades gradually. It's not a switch that flips from normal to impaired. It's a slow drift, measurable if you track the right variables over time.
This is where consumer-grade EEG enters the picture. Clinical EEG requires a hospital visit, trained technicians, and appointments that happen at best a few times per year. A wearable 8-channel EEG device can capture the relevant spectral and coherence data in a five-minute recording session, at home, as often as you want.
The Neurosity Crown's electrode positions at CP3, C3, F5, PO3, PO4, F6, C4, and CP4 cover the frontal, central, and parietal regions where the most diagnostically relevant changes occur. The 256Hz sampling rate provides clean frequency resolution across all relevant bands. And the open SDKs make it possible for researchers and developers to build longitudinal tracking tools that compute and store the biomarkers that matter: alpha peak frequency, power ratios, inter-electrode coherence, and spectral entropy.
To be very clear: a consumer EEG device cannot diagnose Alzheimer's disease. Diagnosis requires clinical evaluation, and the research connecting EEG biomarkers to preclinical Alzheimer's was done with clinical-grade systems and expert analysis. But consumer EEG can do something that clinical systems can't: it can record frequently enough to build a longitudinal baseline and detect subtle trends over months and years.
The 40 Hz Connection
In 2016, a research group at MIT led by Li-Huei Tsai discovered something extraordinary. When they exposed Alzheimer's model mice to flickering light at 40 Hz (a frequency corresponding to gamma brainwaves), it triggered the brain's immune cells, the microglia, to start clearing amyloid-beta plaques. One hour of 40 Hz stimulation reduced amyloid levels in the visual cortex by roughly 50%.
Subsequent studies extended this finding. Combining 40 Hz light with 40 Hz sound produced even more dramatic results, reducing amyloid and tau pathology across multiple brain regions and improving cognitive performance in mouse models. The mechanism appears to involve gamma entrainment, where external stimulation at 40 Hz drives the brain's own gamma oscillations, which in turn activates the glial cells responsible for waste clearance.
Human trials are now underway. Early results from a Phase II clinical trial published in 2024 showed that daily 40 Hz light and sound stimulation over six months slowed brain atrophy and reduced cognitive decline in mild Alzheimer's patients compared to a sham control group. The results weren't a cure, but they were statistically significant, and they opened a completely new avenue for Alzheimer's treatment.
The connection to EEG is direct. Gamma oscillations are measurable on EEG, and the ability to track gamma power and gamma-theta coupling before and after stimulation sessions provides an objective measure of whether the stimulation is actually entraining the brain's circuits. An 8-channel EEG device can capture this data, making it possible to personalize stimulation protocols based on individual brain responses.
The Long Goodbye Doesn't Have to Be Silent
Alzheimer's disease is, at its core, a failure of communication. Proteins misfold. Synapses fail. Neural circuits go dark, one by one, in a predictable sequence that takes decades to complete.
For most of that time, the brain compensates. It reroutes signals around damaged areas, recruits backup circuits, works harder to maintain performance. And from the outside, everything looks fine. The tragedy of Alzheimer's is that by the time the compensation fails and symptoms appear, the underlying damage is already extensive.
But the brain's electrical activity doesn't lie. It can't compensate its way out of a slowed alpha rhythm. It can't fake normal coherence when connections are degrading. The signals are there, subtle but measurable, years before anyone forgets a name or loses their way home.
The question is no longer whether we can detect these early changes. The research says we can. The question is whether we'll build the tools and the habits that make routine brain monitoring as common as checking your blood pressure.
Your brain generates electrical patterns every second of every day. Those patterns contain information about the health and connectivity of the most complex structure in the known universe. For the first time in history, you don't need a hospital to listen. You just need to pay attention.